Clinical experience with COP-1 in multiple sclerosis

M. B. Bornstein; A. Miller; S. Slagle; M. Weitzman; H. Crystal; E. Drexler; M. Keilson; A. Merriam; S. Wassertheil-Smoller; V. Spada; W. Weiss; R. Arnon; I. Jacobsohn; D. Teitelbaum; M. Sela

Clinical experience with COP-1 in multiple sclerosis

M. B. Bornstein, A. Miller, S. Slagle, M. Weitzman, H. Crystal, E. Drexler, M. Keilson, A. Merriam, S. Wassertheil-Smoller, V. Spada, W. Weiss, R. Arnon, I. Jacobsohn, D. Teitelbaum, M. Sela

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

COP-1 is one of a series of polypeptide preparations developed to simulate myelin basic protein (MBP), a natural component of the myelin sheath. MBP in Freund's complete adjuvant induces experimental allergic encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). In saline, MBP suppresses EAE. This is the rationale for the use of COP-1 in MS.

Original language	English
Pages (from-to)	66-69
Number of pages	4
Journal	Neurology
Volume	38
Issue number	7 SUPPL. 2
State	Published - 1988
Externally published	Yes

Cite this

@article{0e091b5a7af74a46b96ae78470072cff,

title = "Clinical experience with COP-1 in multiple sclerosis",

abstract = "COP-1 is one of a series of polypeptide preparations developed to simulate myelin basic protein (MBP), a natural component of the myelin sheath. MBP in Freund's complete adjuvant induces experimental allergic encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). In saline, MBP suppresses EAE. This is the rationale for the use of COP-1 in MS.",

author = "Bornstein, \{M. B.\} and A. Miller and S. Slagle and M. Weitzman and H. Crystal and E. Drexler and M. Keilson and A. Merriam and S. Wassertheil-Smoller and V. Spada and W. Weiss and R. Arnon and I. Jacobsohn and D. Teitelbaum and M. Sela",

year = "1988",

language = "English",

volume = "38",

pages = "66--69",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "7 SUPPL. 2",

}

TY - JOUR

T1 - Clinical experience with COP-1 in multiple sclerosis

AU - Bornstein, M. B.

AU - Miller, A.

AU - Slagle, S.

AU - Weitzman, M.

AU - Crystal, H.

AU - Drexler, E.

AU - Keilson, M.

AU - Merriam, A.

AU - Wassertheil-Smoller, S.

AU - Spada, V.

AU - Weiss, W.

AU - Arnon, R.

AU - Jacobsohn, I.

AU - Teitelbaum, D.

AU - Sela, M.

PY - 1988

Y1 - 1988

N2 - COP-1 is one of a series of polypeptide preparations developed to simulate myelin basic protein (MBP), a natural component of the myelin sheath. MBP in Freund's complete adjuvant induces experimental allergic encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). In saline, MBP suppresses EAE. This is the rationale for the use of COP-1 in MS.

AB - COP-1 is one of a series of polypeptide preparations developed to simulate myelin basic protein (MBP), a natural component of the myelin sheath. MBP in Freund's complete adjuvant induces experimental allergic encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). In saline, MBP suppresses EAE. This is the rationale for the use of COP-1 in MS.

UR - https://www.scopus.com/pages/publications/0023678311

M3 - Article

C2 - 3290717

AN - SCOPUS:0023678311

SN - 0028-3878

VL - 38

SP - 66

EP - 69

JO - Neurology

JF - Neurology

IS - 7 SUPPL. 2

ER -

Clinical experience with COP-1 in multiple sclerosis

Abstract

Fingerprint

Cite this